Answers are grounded in this paper and cite their sources.
The review article discusses the currently used preclinical research methods of angioprotective activity of biologically active substances. Published data indicate the social and economic significance of chronic venous pathologies as a common group of diseases affecting a significant part of the population, characterized by a major risk of complications that require prompt correction. One of the main methods of complex treatment is pharmacotherapy with phlebotropic agents, due to their complex effect on various links of this pathology: increasing vascular tone, reducing pain, improving lymphatic drainage, beneficially affecting all stages of inflammation, membrane-stabilizing and antioxidant effect. The creation and introduction of new and effective medicines of phleboprotective action, including herbal origin, is one of the priority areas of pharmacology and medicine. However, preclinical trials, as one of the long stages of drug development, need optimization. The purpose of the publication: systematization of methods for determining angioprotective activity, consisting of anti-inflammatory, antioxidant, capillary-strengthening activity. The review contains information about the main stages of the preclinical phase of testing – from the search for promising compounds to the developed and used preliminary pharmacological tests to determine biological activity.
No takes yet. Share an insight, caveat, or question.
Timokhina et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: